Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | ASCO 2022: genitourinary cancer highlights

Robert Jones • 4 Jun 2022
ASCO 2022
Bladder Cancer Genitourinary Cancer Urothelial Carcinoma BCG

Robert J. Jones, MD, PhD, University of Glasgow & Beatson West of Scotland Cancer Centre, Glasgow, UK, talks on highlights from the ASCO 2022 meeting in genitourinary (GU) cancer, particularly a trial investigating a IL-15 super agonist in combination with Bacillus Calmette-Guérin (BCG) in the BCG-refractory population of patients with high-risk non-muscle invasive bladder cancer. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Robert Jones

2:04
Areas of unmet need in metastatic urothelial carcinoma
Robert Jones • 4 Jun 2022
0:58
Replacing the current standard of care for urothelial carcinoma
Robert Jones • 4 Jun 2022
2:19
Final results from ATLANTIS cabozantinib arm for urothelial carcinoma
Robert Jones • 4 Jun 2022
2:10
Highlights from PROSCA/BLADDR 2021
Robert Jones • 15 Oct 2021

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals